Twenty percent of children with hepatoblastoma—the most common pediatric liver cancer—face treatment failure when their tumors develop resistance to cisplatin, the standard chemotherapy backbone. Without established second-line treatments, these young patients have limited therapeutic options and poor outcomes.
Researchers identified ATR (ATM and Rad3-related protein kinase) as a critical vulnerability in cisplatin-resistant hepatoblastoma cells. The experimental ATR inhibitor elimusertib demonstrated potent synergy with cisplatin across multiple laboratory models, including patient-derived tumor cultures and three-dimensional spheroid systems that better mimic tumor biology. In animal studies, the elimusertib-cisplatin combination significantly suppressed tumor growth in both transplanted human tumors and genetically-engineered mouse models, while maintaining acceptable toxicity profiles. The combination therapy worked by overwhelming cancer cells with DNA damage—cisplatin creates DNA crosslinks while elimusertib blocks the cellular machinery needed to repair that damage.
This finding addresses a critical gap in pediatric oncology, where treatment options remain limited compared to adult cancers. The research validates ATR inhibition as a promising strategy for chemotherapy-resistant pediatric liver tumors, potentially applicable to other DNA repair-deficient cancers. However, elimusertib remains investigational, requiring clinical trials to establish safety and efficacy in children. The approach represents targeted precision medicine—exploiting specific molecular vulnerabilities rather than broadly toxic approaches. If validated clinically, this combination could transform outcomes for the most challenging hepatoblastoma cases, offering hope to families facing treatment-resistant disease.